Coloplast A/S

CLPBYOTCHealthcare● Active

$5.94

$-0.02(-0.34%)

Market Cap$13.4B

P/E Ratio—

52W High$10.03

52W Low$5.88

Avg Volume690K

Open$5.97

Beta0.52

Free Cash Flow Financials Revenue

Coloplast A/S (CLPBY) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CLPBY · free cash flow · updated Jun 9, 2026

Core FCF metrics

CLPBY · FCF · TTM · margin & CAGR

Free cash flow was $5.03B for FY2025 (fiscal year ending 2025-09-30), up 214.3% year-over-year The FCF margin was 19.2%. Five-year CAGR stands at +5.6%.

FY2025 Free Cash Flow$5.03B▲ +214.3% YoY

Trailing 12M (TTM)$6.04Btrailing 4 quarters sum

FCF Margin19.2%$5.03B ÷ revenue

3-Year CAGR+8.3%FY2022 → FY2025

5-Year CAGR+5.6%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CLPBY · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$6.26B(1.23B)$5.03B▲ +214.3%19.2%

FY2024$2.77B(1.17B)$1.60B▼ 46.4%5.9%

FY2023$4.23B(1.24B)$2.98B▼ 24.7%12.2%

FY2022$5.10B(1.14B)$3.96B▲ +19.3%17.6%

FY2021$5.29B(1.97B)$3.32B▼ 13.2%17.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CLPBY · P/FCF · FCF yield · FCF per share

Coloplast A/S (CLPBY) trades at a FCF yield of 6.98% and a price-to-free-cash-flow ratio of 2.2x. FCF per share stands at $2.68, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

6.98%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$2.68

TTM FCF ÷ Shares Outstanding

Price / FCF

x2.2

Share Price ÷ FCF per Share

EV / FCF (TTM)

x18.2

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-09-30

Cash flow statement summary

CLPBY · cash flow statement · operating / investing / financing

For FY2025, Coloplast A/S generated $6.26B in operating cash flow and spent 1.23B in capital expenditures, yielding $5.03B in free cash flow.

Operating Activities

+$6.26B

Cash from core business operations

2025-09-30

Investing Activities

−$1.18B

CapEx, acquisitions & investments

2025-09-30

Financing Activities

−$4.89B

Buybacks, dividends & debt

2025-09-30

FCF FormulaOperating CF ($6.26B) − |CapEx| (1.23B) = FCF ($5.03B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CLPBY vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Coloplast A/SYOU

CLPBY

$5.03B+214.3%19.2%

26%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Coloplast A/S (CLPBY) reported free cash flow of $5.03B for FY2025 (fiscal year ending 2025-09-30), up 214.3% year-over-year. The FCF margin was 19.2%.

Based on available data, Coloplast A/S has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $5.03B in FY2025. The 5-year CAGR stands at +5.6%.

Coloplast A/S's FCF yield is 6.98% and price-to-FCF ratio is 2.2x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CLPBY free cash flow · 8 questions

Coloplast A/S free cash flow was $5.03B for FY2025, up 214.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $6.04B.

CLPBY free cash flowCLPBY FCFCLPBY FCF 2025CLPBY free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Coloplast A/S · Coloplast A/S SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026